Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 2
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system.
Thomas PWA, West RL, Russel MGVM, Jansen JM, Kosse LJ, Jessurun NT, Römkens TEH, Hoentjen F; IBDREAM registry. Thomas PWA, et al. Among authors: kosse lj. Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):520-524. doi: 10.1002/pds.5175. Epub 2020 Dec 1. Pharmacoepidemiol Drug Saf. 2021. PMID: 33219593 Free PMC article.
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K, Jessurun NT, Nguyen TDM, Scholl J, Jansen JRG, van Lint JA, Kosse LJ, Ten Klooster PM, Vonkeman HE. Velthuis K, et al. Among authors: kosse lj. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):485-492. doi: 10.1080/14740338.2023.2172157. Epub 2023 Jan 27. Expert Opin Drug Saf. 2023. PMID: 36683590
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
Roest LH, Kosse LJ, van Lint JA, Gosselt HR, Scholl JHG, van Puijenbroek E, Vonkeman HE, Tas SW, Nurmohamed MT, van den Bemt BJF, Jessurun NT. Roest LH, et al. Among authors: kosse lj. Expert Opin Drug Saf. 2023 Mar;22(3):203-211. doi: 10.1080/14740338.2022.2115479. Epub 2022 Aug 28. Expert Opin Drug Saf. 2023. PMID: 36036179